Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05167422 · ClinicalTrials.gov registry record · NA
Trusted Messenger Intervention
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT05167422: Clinical Trial NA study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT05167422 is a NA study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05167422, a NA study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The objective of this pilot study is to develop and evaluate test a trusted messenger intervention targeting vaccine hesitancy in patients on an inpatient psychiatric hospital setting with both acute and chronic patients.
Primary Outcome
The participant is willing to receive the COVID-19 vaccine
Interventions
- BEHAVIORAL Trusted Messenger
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2023-07-14 |
| Phase | NA |
Why NCT05167422 stopped before completion
NCT05167422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Trusted Messenger is the first listed.
NCT05167422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05167422 about?
NCT05167422 is a clinical study titled "Trusted Messenger Intervention". The objective of this pilot study is to develop and evaluate test a trusted messenger intervention targeting vaccine hesitancy in patients on an inpatient psychiatric hospital setting with both acute and chronic patients.
What is the current status of trial NCT05167422?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2021-09-14. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05167422?
The interventions under investigation include: Trusted Messenger (BEHAVIORAL).
Who is sponsoring clinical trial NCT05167422?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05167422's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI